PEXA AB PExA AB Share Price Deutsche Boerse AG
Equities
FA0
SE0007412374
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0338 EUR | -11.98% |
|
-11.05% | -8.65% |
| 15/05 | PExA AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 21/02 | PExA AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2021 | 21.61L 2L 2L 1.71Cr | Sales 2022 | 60.27L 6L 5L 4.78Cr | Capitalization | 2.72Cr 25.85L 23.92L 22Cr |
|---|---|---|---|---|---|
| Net income 2021 | -70L -7L -6L -5.55Cr | Net income 2022 | -40L -4L -4L -3.17Cr | EV / Sales 2021 | 13.5 x |
| Net cash position 2021 | 2.07Cr 19.67L 18.21L 16Cr | Net cash position 2022 | 1.82Cr 17.32L 16.04L 14Cr | EV / Sales 2022 | 1.49 x |
| P/E ratio 2021 |
-4.95
x | P/E ratio 2022 |
-5.73
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -11.98% | ||
| 1 week | -11.05% | ||
| Current month | -11.05% | ||
| 1 month | +10.46% | ||
| 3 months | -10.11% | ||
| 6 months | -6.63% | ||
| Current year | -8.65% |
1 week
0.03
0.04
1 month
0.030.04
Current year
0.030.05
1 year
0.030.05
3 years
0.030.05
5 years
0.030.05
10 years
0.030.05
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | - | |
Jörgen Östling
CTO | Chief Tech/Sci/R&D Officer | - | - |
Svante Höjer
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 01/18/01 | |
| Director/Board Member | 71 | 01/21/01 | |
| Chairman | 70 | 01/12/01 |
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 0.0338 | -11.98% |
| 06/24/06 | 0.0384 | +7.26% |
| 05/24/05 | 0.0358 | -0.56% |
| 04/24/04 | 0.036 | -4.26% |
| 03/24/03 | 0.0376 | -1.05% |
Delayed Quote Deutsche Boerse AG, June 07, 2024 at 06:59 pm IST
More quotes
PExA AB is a Sweden-based company engaged in the advanced equipment and technology industry. The Company develops, manufactures and markets a non-invasive research instrument to study respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The instrument provides lung researchers with a non-invasive method for collecting microscopic particles, potential biomarkers for diseases, from small airways in exhaled air to diagnose, monitor and provide treatment of respiratory diseases.
Calendar
20/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.77% | 1.68TCr | |
| -43.46% | 285.17Cr | |
| +22.46% | 195.56Cr | |
| -12.32% | 146.15Cr | |
| +31.49% | 133.55Cr | |
| -16.15% | 94Cr | |
| +1.33% | 81Cr | |
| -31.07% | 77Cr | |
| -25.95% | 64Cr |
- Stock Market
- Equities
- PEXA B Stock
- FA0 Stock
